Aurinia Pharmaceuticals Inc (AUPH)
5.10
-0.07
(-1.35%)
USD |
NASDAQ |
May 03, 16:00
5.095
0.00 (0.00%)
After-Hours: 20:00
Aurinia Pharmaceuticals Cash from Financing (Quarterly): -5.577M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -5.577M |
| September 30, 2023 | -2.332M |
| June 30, 2023 | 1.14M |
| March 31, 2023 | 1.639M |
| December 31, 2022 | 0.688M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 1.34M |
| March 31, 2022 | 0.405M |
| December 31, 2021 | 205.72M |
| September 30, 2021 | 9.082M |
| June 30, 2021 | 1.279M |
| March 31, 2021 | 5.029M |
| December 31, 2020 | 1.242M |
| September 30, 2020 | 189.26M |
| June 30, 2020 | 0.954M |
| March 31, 2020 | 2.922M |
| December 31, 2019 | 196.92M |
| September 30, 2019 | 14.85M |
| June 30, 2019 | 0.435M |
| March 31, 2019 | 31.65M |
| December 31, 2018 | 0.612M |
| September 30, 2018 | 0.008M |
| June 30, 2018 | 3.394M |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.055M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.243M |
| June 30, 2017 | 1.674M |
| March 31, 2017 | 172.18M |
| December 31, 2016 | 28.54M |
| September 30, 2016 | 7.435M |
| June 30, 2016 | 6.64M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.056M |
| June 30, 2015 | 0.414M |
| March 31, 2015 | 0.369M |
| December 31, 2014 | 0.542M |
| September 30, 2014 | 0.477M |
| June 30, 2014 | 0.034M |
| March 31, 2014 | 46.84M |
| December 31, 2013 | -0.006M |
| September 30, 2013 | 5.527M |
| June 30, 2013 | 0.862M |
| March 31, 2013 | -0.008M |
| December 31, 2012 | 0.7502M |
| September 30, 2012 | -0.0119M |
| June 30, 2012 | -0.0106M |
| March 31, 2012 | -0.011M |
| December 31, 2011 | 0.0252M |
| September 30, 2011 | -0.1612M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-5.577M
Minimum
Dec 2023
205.72M
Maximum
Dec 2021
32.89M
Average
1.279M
Median
Jun 2021
Cash from Financing (Quarterly) Benchmarks
| Lexaria Bioscience Corp | 3.453M |
| Acasti Pharma Inc | 0.00 |
| Edesa Biotech Inc | 0.3057M |
| Xenon Pharmaceuticals Inc | 324.01M |
| ESSA Pharma Inc | 0.1967M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 14.31M |
| Cash from Investing (Quarterly) | -6.257M |
| Free Cash Flow | -34.18M |
| Free Cash Flow Per Share (Quarterly) | 0.0992 |
| Free Cash Flow to Equity (Quarterly) | 14.25M |
| Free Cash Flow to Firm (Quarterly) | 14.25M |
| Free Cash Flow Yield | -4.69% |